½ÃÀ庸°í¼­
»óǰÄÚµå
1642801

Àå±â º¸Á¸ ½ÃÀå : ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Çâ, ¿¹Ãø - º¸Á¸ ¼Ö·ç¼Çº°, Àå±â Á¦°ø À¯Çüº°, ¼ö¹ýº°, Àå±â À¯Çüº°, ÃÖÁ¾ »ç¿ëÀÚº°, Áö¿ªº°(2025-2033³â)

Organ Preservation Market Size, Share, Trends and Forecast by Preservation Solution, Organ Donation Type, Technique, Organ Type, End-User, and Region, 2025-2033

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: IMARC | ÆäÀÌÁö Á¤º¸: ¿µ¹® 126 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°èÀÇ Àå±â º¸Á¸ ½ÃÀå ±Ô¸ð´Â 2024³â 1¾ï 9,887¸¸ ´Þ·¯°¡ µÆ½À´Ï´Ù. IMARC GroupÀº ÇâÈÄ ½ÃÀåÀÌ 2033³â±îÁö 3¾ï 2,040¸¸ ´Þ·¯¿¡ À̸¦ Àü¸ÁÀ̸ç, 2025³âºÎÅÍ 2033³â±îÁö 5.39%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)À» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹ÃøÇß½À´Ï´Ù. ÇöÀç ½ÃÀåÀ» µ¶Á¡Çϰí ÀÖ´Â °ÍÀº ºÏ¹ÌÀ̸ç, 2024³â ½ÃÀå Á¡À¯À²Àº 45.9%¸¦ ³Ñ¾ú½À´Ï´Ù. ºÏ¹ÌÀÇ ¼ºÀå ¿øµ¿·ÂÀº ÷´Ü °Ç°­ °ü¸® ÀÎÇÁ¶ó, Àå±â ÀÌ½Ä Áõ°¡, ±â¼ú Áøº¸, Á¤ºÎÀÇ Áö¿øÃ¥ÀÔ´Ï´Ù.

Àå±â º¸Á¸À̶õ ±âÁõÀÚÀÇ Ã¼³»¿¡¼­ äÃëÇÑ °Ç°­ÇÑ Àå±â¸¦ º¸Á¸ÇÏ´Â °úÁ¤À» ¸»ÇÕ´Ï´Ù. ÀÌ °úÁ¤¿¡¼­ ±âÁõÀÚÀÇ Ã¼³»¿¡¼­ Àå±â¸¦ Á¦°ÅÇÏ°í ¿î¼ÛÀ» À§ÇØ º¸°üÇÑ ÈÄ, Å« ¼Õ»óÀ» ÁÖÁö ¾ÊÀ¸¸é¼­ ¼ö·ÉÀÎÀÇ Ã¼³»¿¡ À̽ÄÇÕ´Ï´Ù. ½ÅÀå, °£, Æó, ½ÉÀå ¹× ±âŸ Àå±âÀÇ ¿Âµµ¿Í »ê¼Ò ¼öÁØÀ» À¯ÁöÇϱâ À§ÇØ Àúü¿Â ±â°è °ü·ù, Á¤Àû Àú¿Â º¸Á¸(SCS), Á¤»ó ü¿Â ±â°è °ü·ù(NMP) µî ´Ù¾çÇÑ ±â¼úÀÌ »ç¿ëµË´Ï´Ù. »ç¿ëµÇ´Â º¸Á¸ ±â¼ú°ú ¿ë¾×Àº ÀÌ½Ä ÈÄ È¯ÀÚÀÇ ÀÌȯÀ²°ú »ýÁ¸À²¿¡ Á÷Á¢ ¿µÇâÀ» ¹ÌÄ¡´Â ±âÁõÀÚ Àå±âÀÇ Ç°Áú¿¡ ÇʼöÀûÀÔ´Ï´Ù.

Àå±â º¸Á¸ ½ÃÀå µ¿Çâ :

¸¸¼º ÁúȯÀÇ À¯º´·ü Áõ°¡´Â ¼¼°è ³ëÀÎ Àα¸ Áõ°¡¿Í ÇÔ²² ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÏ´Â ÁÖ¿ä ¿äÀÎ Áß ÇϳªÀÔ´Ï´Ù. ´ç´¢º´, ½ÉÇ÷°ü Àå¾Ö(CVDs), ºñ¸¸ ¹× ±âŸ ½É°¢ÇÑ º´¸®·Î ÀÎÇØ Àå±â ºÎÀüÀÌ ÀÚÁÖ ¹ß»ýÇϱ⠶§¹®¿¡ Àå±â ¿ÂÁ¸ÀÇ Çʿ伺ÀÌ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. Àå±â º¸Á¸À» À§ÇÑ NMP¿Í °°Àº Çõ½ÅÀûÀÌ°í °í±Þ ±â¼úÀÇ ÃâÇöÀº ¼ºÀåÀ» °¡¼ÓÇÏ´Â ¿äÀÎÀ¸·Î ÀÛ¿ëÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ±â¼úÀº ÀÌ½Ä Áß Àç°ü·ù Àå¾ÖÀÇ È®·üÀ» °¨¼Ò½ÃŰ´Â µ¥ µµ¿òÀÌ µÇ¾úÀ¸¸ç ÀÓ»ó ¹× ½ÇÇèÀû ¿¬±¸¸¦ À§ÇÑ Àú¿Â º¸Á¸¿¡¼­ °³¼±µÈ °á°ú¸¦ º¸¿©ÁÝ´Ï´Ù. ¶ÇÇÑ Àå±â Á¦°øÀ» ÃËÁøÇÏ´Â Á¤ºÎ ¹× ºñÁ¤ºÎ Á¤Ã¥°ú ÀÌ´Ï¼ÅÆ¼ºê Áõ°¡°¡ ½ÃÀå ¼ºÀå¿¡ ±àÁ¤Àû ¿µÇâÀ» ¹ÌĨ´Ï´Ù. À̽ÄÀ̳ª ¿¬±¸ ¸ñÀûÀ¸·Î Àå±â Á¦°øÀ» Áö¿øÇÏ´Â °³ÀÎ Áõ°¡µµ ½ÃÀåÀ» ´õ¿í °ßÀÎÇϰí ÀÖ½À´Ï´Ù. ¿¬±¸°³¹ß(R&D)ÀÇ °­È­³ª Àå±âº¸Á¸ ÀÎÇÁ¶óÀÇ ´ëÆøÀûÀÎ Áøº¸ µî ±âŸ ¿äÀεµ ½ÃÀå ¼ºÀå¿¡ Å©°Ô °øÇåÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹üÀ§ ¹× Á¶»ç ¹æ¹ý

  • Á¶»çÀÇ ¸ñÀû
  • ÀÌÇØ°ü°èÀÚ
  • µ¥ÀÌÅÍ ¼Ò½º
    • 1Â÷ Á¤º¸
    • 2Â÷ Á¤º¸
  • ½ÃÀå ÃßÁ¤
    • »óÇâ½Ä Á¢±Ù
    • ÇÏÇâ½Ä Á¢±Ù
  • Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ¼­¹®

  • °³¿ä
  • ÁÖ¿ä ¾÷°è µ¿Çâ

Á¦5Àå ¼¼°èÀÇ Àå±â º¸Á¸ ½ÃÀå

  • ½ÃÀå °³¿ä
  • ½ÃÀå ½ÇÀû
  • COVID-19ÀÇ ¿µÇâ
  • ½ÃÀå ¿¹Ãø

Á¦6Àå ½ÃÀå ³»¿ª : º¸Á¸ ¼Ö·ç¼Çº°

  • UW ¼Ö·ç¼Ç
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • Custodiol HTK
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • Perfadex
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • ±âŸ
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø

Á¦7Àå ½ÃÀå ³»¿ª : Àå±â Á¦°ø À¯Çüº°

  • »ýü Àå±â Á¦°ø
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • ½Ãü Àå±â Á¦°ø
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø

Á¦8Àå ½ÃÀå ³»¿ª : ¼ö¹ýº°

  • Á¤Àû ³ÃÀå
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • Àúü¿Â ¸Ó½Å °ü·ù
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • »ó¿Â±â°è °ü·ù
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • ±âŸ
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø

Á¦9Àå ½ÃÀå ³»¿ª : Àå±âº°

  • ½ÅÀå
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • °£
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • Æó
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • ½ÉÀå
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • ±âŸ
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø

Á¦10Àå ½ÃÀå ³»¿ª : ÃÖÁ¾ »ç¿ëÀÚº°

  • º´¿ø ¹× Áø·á¼Ò
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • Àå±â ¹ðÅ©
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • ±âŸ
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø

Á¦11Àå ½ÃÀå ³»¿ª : Áö¿ªº°

  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
    • ÀϺ»
    • Àεµ
    • Çѱ¹
    • È£ÁÖ
    • Àεµ³×½Ã¾Æ
    • ±âŸ
  • À¯·´
    • µ¶ÀÏ
    • ÇÁ¶û½º
    • ¿µ±¹
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • ·¯½Ã¾Æ
    • ±âŸ
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ±âŸ
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ³»¿ª : ±¹°¡º°
    • ½ÃÀå ¿¹Ãø

Á¦12Àå SWOT ºÐ¼®

  • °³¿ä
  • °­Á¡
  • ¾àÁ¡
  • ±âȸ
  • À§Çù

Á¦13Àå ¹ë·ùüÀÎ ºÐ¼®

Á¦14Àå Porter's Five Forces ºÐ¼®

  • °³¿ä
  • ±¸¸ÅÀÚÀÇ Çù»ó·Â
  • °ø±Þ±â¾÷ÀÇ Çù»ó·Â
  • °æÀïµµ
  • ½Å±Ô Âü°¡¾÷üÀÇ À§Çù
  • ´ëüǰÀÇ À§Çù

Á¦15Àå °¡°Ý ÁöÇ¥

Á¦16Àå °æÀï ±¸µµ

  • ½ÃÀå ±¸Á¶
  • ÁÖ¿ä ±â¾÷
  • ÁÖ¿ä ±â¾÷ ÇÁ·ÎÆÄÀÏ
    • 21st Century Medicine Inc.
    • Biolife Solutions Inc.
    • Bridge to Life Ltd.
    • Bristol-Myers
    • Dr. Franz Kohler Chemie GmbH
    • Essential Pharmaceuticals LLC
    • Lifeline Scientific Inc.
    • OrganOx Ltd.
    • Paragonix Technologies Inc.
    • Transmedics, Inc.
    • Waters Medical Systems LLC
    • Xvivo Perfusion
AJY 25.03.10

The global organ preservation market size was valued at USD 198.87 Million in 2024. Looking forward, IMARC Group estimates the market to reach USD 320.40 Million by 2033, exhibiting a CAGR of 5.39% from 2025-2033. North America currently dominates the market, holding a market share of over 45.9% in 2024. The growth of the North American region is driven by advanced healthcare infrastructure, rising organ transplants, technological advancements, and supportive government initiatives.

Organ preservation refers to the process of preserving healthy organs harvested from the body of donors. The process involves the removal of organs from the donor's body, storing it for transportation and then transplanting it into the receiver's body without significant damage. It utilizes various techniques, such as hypothermic machine perfusion, static cold storage (SCS) and normothermic machine perfusion (NMP), to maintain the temperature and oxygen levels of kidneys, liver, lung, heart and other organs. The preservation techniques and solutions used are essential for donor organ quality, which directly influences the morbidity and survival rates of a patient after transplantation.

Organ Preservation Market Trends:

The increasing prevalence of chronic diseases, along with the growing geriatric population across the globe, are among the key factors driving the growth of the market. Owing to the frequent occurrences of organ failures due to diabetes, cardiovascular disorders (CVDs), obesity, and other such severe medical conditions, there is an increasing need for organ preservation procedures. The advent of innovative and advanced techniques, such as NMP, for organ preservation, is acting as a growth-inducing factor. Such techniques aid in decreasing the probability of reperfusion injury during transplantation and exhibits improved results in cold storage for clinical and experimental studies. Moreover, an increasing number of government and non-government policies and initiatives to promote organ donation are impacting the market growth positively. The rising number of individuals volunteering to donate their organs for transplantation and research purposes are also driving the market further. Other factors, including enhanced research and development (R&D) and significant advancements in the organ preservation infrastructure, are also projected to contribute to the market growth significantly.

Organ Preservation Industry Segmentation:

Breakup by Preservation Solution:

UW Solution

Custodiol HTK

Perfadex

Others

Breakup by Organ Donation Type:

Living Organ Donation

Deceased Organ Donation

Breakup by Technique:

Static Cold Storage Technique

Hypothermic Machine Perfusion

Normothermic Machine Perfusion

Others

Breakup by Organ Type:

Kidney

Liver

Lung

Heart

Others

Breakup by End-User:

Hospitals and Clinics

Organ Banks

Others

Breakup by Region:

North America

United States

Canada

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The report has also analysed the competitive landscape of the market with some of the key players being 21st Century Medicine, Biolife Solutions, Bridge to Life Ltd., Bristol-Myers Squibb, Dr. Franz Kohler Chemie GmbH, Essential Pharmaceuticals., Lifeline Scientific, OrganOx, Paragonix Technologies, TransMedics, Waters Medical Systems, Xvivo Perfusion, etc.

Key Questions Answered in This Report

  • 1. What is organ preservation?
  • 2. How big is the global organ preservation market?
  • 3. What is the expected growth rate of the global organ preservation market during 2025-2033?
  • 4. What are the key factors driving the global organ preservation market?
  • 5. What is the leading segment of the global organ preservation market based on preservation solution?
  • 6. What is the leading segment of the global organ preservation market based on organ donation type?
  • 7. What is the leading segment of the global organ preservation market based on technique?
  • 8. What is the leading segment of the global organ preservation market based on organ type?
  • 9. What is the leading segment of the global organ preservation market based on end-user?
  • 10. What are the key regions in the global organ preservation market?
  • 11. Who are the key players/companies in the global organ preservation market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Organ Preservation Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Preservation Solution

  • 6.1 UW Solution
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Custodiol HTK
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Perfadex
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Others
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast

7 Market Breakup by Organ Donation Type

  • 7.1 Living Organ Donation
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Deceased Organ Donation
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Technique

  • 8.1 Static Cold Storage Technique
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Hypothermic Machine Perfusion
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Normothermic Machine Perfusion
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Others
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by Organ Type

  • 9.1 Kidney
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Liver
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Lung
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast
  • 9.4 Heart
    • 9.4.1 Market Trends
    • 9.4.2 Market Forecast
  • 9.5 Others
    • 9.5.1 Market Trends
    • 9.5.2 Market Forecast

10 Market Breakup by End-User

  • 10.1 Hospitals and Clinics
    • 10.1.1 Market Trends
    • 10.1.2 Market Forecast
  • 10.2 Organ Banks
    • 10.2.1 Market Trends
    • 10.2.2 Market Forecast
  • 10.3 Others
    • 10.3.1 Market Trends
    • 10.3.2 Market Forecast

11 Market Breakup by Region

  • 11.1 North America
    • 11.1.1 United States
      • 11.1.1.1 Market Trends
      • 11.1.1.2 Market Forecast
    • 11.1.2 Canada
      • 11.1.2.1 Market Trends
      • 11.1.2.2 Market Forecast
  • 11.2 Asia Pacific
    • 11.2.1 China
      • 11.2.1.1 Market Trends
      • 11.2.1.2 Market Forecast
    • 11.2.2 Japan
      • 11.2.2.1 Market Trends
      • 11.2.2.2 Market Forecast
    • 11.2.3 India
      • 11.2.3.1 Market Trends
      • 11.2.3.2 Market Forecast
    • 11.2.4 South Korea
      • 11.2.4.1 Market Trends
      • 11.2.4.2 Market Forecast
    • 11.2.5 Australia
      • 11.2.5.1 Market Trends
      • 11.2.5.2 Market Forecast
    • 11.2.6 Indonesia
      • 11.2.6.1 Market Trends
      • 11.2.6.2 Market Forecast
    • 11.2.7 Others
      • 11.2.7.1 Market Trends
      • 11.2.7.2 Market Forecast
  • 11.3 Europe
    • 11.3.1 Germany
      • 11.3.1.1 Market Trends
      • 11.3.1.2 Market Forecast
    • 11.3.2 France
      • 11.3.2.1 Market Trends
      • 11.3.2.2 Market Forecast
    • 11.3.3 United Kingdom
      • 11.3.3.1 Market Trends
      • 11.3.3.2 Market Forecast
    • 11.3.4 Italy
      • 11.3.4.1 Market Trends
      • 11.3.4.2 Market Forecast
    • 11.3.5 Spain
      • 11.3.5.1 Market Trends
      • 11.3.5.2 Market Forecast
    • 11.3.6 Russia
      • 11.3.6.1 Market Trends
      • 11.3.6.2 Market Forecast
    • 11.3.7 Others
      • 11.3.7.1 Market Trends
      • 11.3.7.2 Market Forecast
  • 11.4 Latin America
    • 11.4.1 Brazil
      • 11.4.1.1 Market Trends
      • 11.4.1.2 Market Forecast
    • 11.4.2 Mexico
      • 11.4.2.1 Market Trends
      • 11.4.2.2 Market Forecast
    • 11.4.3 Others
      • 11.4.3.1 Market Trends
      • 11.4.3.2 Market Forecast
  • 11.5 Middle East and Africa
    • 11.5.1 Market Trends
    • 11.5.2 Market Breakup by Country
    • 11.5.3 Market Forecast

12 SWOT Analysis

  • 12.1 Overview
  • 12.2 Strengths
  • 12.3 Weaknesses
  • 12.4 Opportunities
  • 12.5 Threats

13 Value Chain Analysis

14 Porters Five Forces Analysis

  • 14.1 Overview
  • 14.2 Bargaining Power of Buyers
  • 14.3 Bargaining Power of Suppliers
  • 14.4 Degree of Competition
  • 14.5 Threat of New Entrants
  • 14.6 Threat of Substitutes

15 Price Indicators

16 Competitive Landscape

  • 16.1 Market Structure
  • 16.2 Key Players
  • 16.3 Profiles of Key Players
    • 16.3.1 21st Century Medicine Inc.
      • 16.3.1.1 Company Overview
      • 16.3.1.2 Product Portfolio
    • 16.3.2 Biolife Solutions Inc.
      • 16.3.2.1 Company Overview
      • 16.3.2.2 Product Portfolio
      • 16.3.2.3 Financials
    • 16.3.3 Bridge to Life Ltd.
      • 16.3.3.1 Company Overview
      • 16.3.3.2 Product Portfolio
    • 16.3.4 Bristol-Myers
      • 16.3.4.1 Company Overview
      • 16.3.4.2 Product Portfolio
      • 16.3.4.3 Financials
      • 16.3.4.4 SWOT Analysis
    • 16.3.5 Dr. Franz Kohler Chemie GmbH
      • 16.3.5.1 Company Overview
      • 16.3.5.2 Product Portfolio
      • 16.3.5.3 Financials
    • 16.3.6 Essential Pharmaceuticals LLC
      • 16.3.6.1 Company Overview
      • 16.3.6.2 Product Portfolio
    • 16.3.7 Lifeline Scientific Inc.
      • 16.3.7.1 Company Overview
      • 16.3.7.2 Product Portfolio
    • 16.3.8 OrganOx Ltd.
      • 16.3.8.1 Company Overview
      • 16.3.8.2 Product Portfolio
      • 16.3.8.3 Financials
    • 16.3.9 Paragonix Technologies Inc.
      • 16.3.9.1 Company Overview
      • 16.3.9.2 Product Portfolio
    • 16.3.10 Transmedics, Inc.
      • 16.3.10.1 Company Overview
      • 16.3.10.2 Product Portfolio
    • 16.3.11 Waters Medical Systems LLC
      • 16.3.11.1 Company Overview
      • 16.3.11.2 Product Portfolio
    • 16.3.12 Xvivo Perfusion
      • 16.3.12.1 Company Overview
      • 16.3.12.2 Product Portfolio
      • 16.3.12.3 Financials
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦